Principal Financial Group Inc. Has $9.99 Million Position in Omnicell, Inc. (NASDAQ:OMCL)

Principal Financial Group Inc. lessened its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 11.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 229,089 shares of the company’s stock after selling 31,062 shares during the quarter. Principal Financial Group Inc. owned 0.50% of Omnicell worth $9,988,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of OMCL. Arizona State Retirement System increased its position in shares of Omnicell by 2.9% during the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after acquiring an additional 357 shares during the last quarter. Diversified Trust Co increased its position in shares of Omnicell by 3.3% during the 2nd quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after purchasing an additional 494 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the period. Louisiana State Employees Retirement System grew its position in Omnicell by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after buying an additional 600 shares during the period. Finally, ProShare Advisors LLC grew its position in Omnicell by 7.4% during the first quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after buying an additional 626 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Craig Hallum upped their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Barclays increased their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Benchmark reissued a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Wells Fargo & Company upped their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Finally, Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $50.83.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $46.05 on Tuesday. The company has a market cap of $2.13 billion, a P/E ratio of -117.10, a PEG ratio of 43.97 and a beta of 0.81. The stock’s fifty day moving average price is $44.20 and its 200-day moving average price is $36.96. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.